A blood test detecting antibodies to gut bacteria may predict Crohn’s disease risk years before symptoms appear, offering a potential breakthrough in early intervention.
Researchers found that elevated antibodies to flagellin—a protein in gut bacteria—were present in 36.4% of individuals who later developed Crohn’s disease, based on a study of 381 first-degree relatives of patients. The average time between blood sampling and diagnosis was 2.5 years.
Dr. Ken Croitoru said:
"With all of the advanced biologic therapy we have today, patients' responses are partial at best. We haven't cured anybody yet, and we need to do better."
Dr. Sun-Ho Lee added:
"Confirming our previous study immune response against bacterial flagellins show strong associations with future risk of Crohn’s in healthy first-degree relatives."
The GEM Project, which tracked over 5,000 relatives, identified immune responses to Lachnospiraceae bacteria as a potential early marker. However, the study’s focus on first-degree relatives limits its generalizability, and experts caution further research is needed before clinical application.
Researchers suggest flagellin-targeted vaccines could prevent disease in high-risk individuals, pending validation.
⚠️ LEGAL DISCLAIMER: It is for informational purposes only. It never substitutes for professional medical advice, diagnosis, or treatment. Always consult your doctor regarding any questions about your health.